| Patient | Julius Caesar |
|---|---|
| Date of birth | 1972-07-12 |
| Identifiers | MRN HR-AC001-SYN; SSN (made up) 000-01-6022 |
| Document date | 2026-10-27 |
| Author | Lucius Fairbanks-Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Ten-week review: seizure control, lipids, blood pressure, and driving. [S]
Julius Caesar returns ten weeks after starting levetiracetam, atorvastatin, and aspirin, and six weeks after amlodipine was added. He has had no seizure, spell, or confused awakening, and has missed no doses. He has had slight ankle swelling in the evenings, which he does not mind. His home readings are 118 to 128 over 72 to 80. He has no muscle aches, bleeding, or bruising, and his mood is good. He asks when he can drive again and whether he can stop any of the medicines in time. [S]
| Element | Detail |
|---|---|
| Seizures | None for ten weeks |
| Home blood pressure | 118 to 128 over 72 to 80 |
| Side effects | Slight evening ankle swelling on amlodipine |
| Questions | Driving; how long the medicines are needed |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Slight evening ankle swelling; no chest pain or breathlessness |
| Musculoskeletal | Negative | No muscle aches |
| Neurological | Negative | No spell or new symptom |
| Psychiatric | Negative | Mood good; PHQ-9 3 |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Lisinopril 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth each morning | Oral route | 2026-08-04 | active | S |
| Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily | 500 mg twice daily, morning and evening | Oral route | 2026-08-18 | active | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth at bedtime | One tablet by mouth at bedtime | Oral route | 2026-08-18 | active | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth daily | One tablet by mouth daily with food | Oral route | 2026-08-18 | active | S |
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours as needed for fever or sore throat (no more than 3 g a day) | One or two tablets every 6 hours as needed, at most 3 g a day, for up to a week | Oral route | 2026-09-08 to 2026-09-14 | completed | S |
| Amlodipine 5 mg oral tablet, one tablet by mouth daily | One tablet by mouth each morning | Oral route | 2026-09-15 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-27 | Body height | 182 | cm | S |
| 2026-10-27 | Body weight | 75 | kg | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 22.6 | kg/m2 | S |
| 2026-10-27 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-10-27 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-27 | Heart rate | 66 | /min | S |
| 2026-10-27 | Respiratory rate | 14 | /min | S |
| 2026-10-27 | Body temperature | 36.6 | Cel | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-27 | Cholesterol [Mass/volume] in Serum or Plasma | 136 | mg/dL | <=200 mg/dL | Normal | S |
| 2026-10-27 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-10-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 68 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-10-27 | Triglyceride [Mass/volume] in Serum or Plasma | 110 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-10-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 34 | U/L | 7-56 U/L | Normal | S |
| 2026-10-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 2026-10-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Cardiovascular | Regular rhythm; blood pressure 124/76 mmHg; trace ankle edema |
| Neurological | No focal deficit |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent transient episodes of collapse: six days ago a witnessed collapse with stiffening and jerking of both arms for about a minute, a bitten tongue, and about twenty minutes of confusion, after a rising strange feeling and dizziness; two briefer spells of staring and unresponsiveness in the past eighteen months; cause not yet known (seizure, convulsive syncope, or transient ischemic attack) | resolved | confirmed | R56.9 | S — Synthetic presenting problem anchored to the documented accounts of falling attacks and fainting fits; it resolves when the cause is found. |
| Hypertension, stage 2: 152/94 and 148/92 mmHg today; told of high blood pressure about three years ago and never treated | active | confirmed | I10 | S — Synthetic vascular risk factor; no blood pressure from his lifetime is known. |
| Hyperlipidemia: LDL 158 mg/dL, triglycerides 170 mg/dL, HDL 44 mg/dL | active | confirmed | E78.5 | S — Synthetic vascular risk factor; no lipid value from his lifetime is known. |
| Focal epilepsy with a structural vascular cause: focal impaired-awareness seizures with automatisms, one evolving to a bilateral tonic-clonic seizure, arising from a chronic left temporal cortical infarct, with left temporal sharp waves on EEG | active | confirmed | G40.209 | S — Synthetic modern diagnosis anchored to the documented falling attacks; the ILAE 2017 seizure types and a structural cause are chosen for teaching and make no claim about what he had. |
| Chronic left posterior temporal cortical infarct, not recognized before the seizures, with moderate small-vessel white matter disease and a non-stenotic left carotid plaque; no residual deficit | active | confirmed | I69.398 | S — Synthetic modern finding anchored to the retrospective cerebrovascular hypothesis; it makes no claim about his real brain. |
| Acute viral upper respiratory infection with low-grade fever and poor sleep, three weeks after starting levetiracetam; rapid COVID-19 and influenza tests negative; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness, chosen to teach cold-remedy choices with hypertension, aspirin, and an antiseizure medicine, and sleep loss as a seizure trigger; it echoes no documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (target below 130/80 mmHg) | Every visit | Completed today | 124/76 mmHg; home 118 to 128 over 72 to 80 |
| Laboratory | Lipid panel after starting a statin | 4 to 12 weeks after starting, then every 3 to 12 months | Completed today | LDL 68 mg/dL (target below 70); total cholesterol 136, HDL 46, triglycerides 110 mg/dL |
| Medication safety | Statin tolerance and liver tests | At the first lipid check, then with symptoms | Completed today | ALT 34 U/L; no muscle aches |
| Survey | Depression screen (PHQ-9) | Periodically, at least yearly | Completed today | 3; item 9 scored 0 |
| Laboratory | Potassium and creatinine | Yearly on an ACE inhibitor once stable | Up to date | Normal after the start; next in a year |
| Laboratory | Diabetes screen | Periodically after a stroke without diabetes | Up to date | HbA1c 5.6 percent at intake; repeat yearly |
| Medication safety | Influenza vaccination | Yearly | Up to date | Given at the preventive visit three weeks ago |
| Survey | Cognitive screen (MoCA) | In the first year, then periodically | Up to date | 28 of 30 six weeks ago |
| Medication safety | Antithrombotic adherence and bleeding | Every visit | Completed today | Aspirin daily; no bleeding |
| Medication safety | Antiseizure medicine: seizures, adherence, and side effects | Every visit | Completed today | No seizure for ten weeks; no side effects now |
| Examination | Fall risk | Every visit | Completed today | No falls |
| Examination | Weight and BMI | Every visit | Completed today | 75.0 kg; BMI 22.6 |
| Self-management | Tobacco, alcohol, physical activity, and diet | Every visit | Completed today | Diet and walking kept up; alcohol unchanged; never smoker |
| Self-management | Seizure safety and driving | Every visit | Completed today | Not driving; review at six seizure-free months with neurology; riding only with a companion |
Goal progress:
Guideline basis: Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society (2015); Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy (2018); 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (2021); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018); CMID: Clinical Monitoring Intelligence Database, stroke and transient ischemic attack, hypertension, and hyperlipidemia monographs (2026)
Follow-up: Chronic-care visit in three months; neurology review at six months; lipid panel in six months; next preventive visit in a year. [S]